We Can Medicines (6929) reported revenue of NT$284 million for Oct 2026, +4.5% year on year and +6.6% from the previous month. Revenue for Jan–Oct 2026 was NT$2.7 billion (+0.7% year on year).
Year-on-year revenue growth: 4 months in a row. →
In Oct 2026, it ranked No. 34 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$284 million | +4.5% | +6.6% |
| Sep 2026 | NT$266.4 million | +5.2% | -3.2% |
| Aug 2026 | NT$275.4 million | +2.0% | +2.0% |
| Jul 2026 | NT$270 million | +1.3% | +4.9% |
| Jun 2026 | NT$257.4 million | -4.3% | -9.0% |
| May 2026 | NT$282.9 million | -0.2% | +7.8% |
| Apr 2026 | NT$262.3 million | -0.8% | -3.6% |
| Mar 2026 | NT$272 million | +2.5% | +4.6% |
| Feb 2026 | NT$260 million | +3.8% | -1.8% |
| Jan 2026 | NT$264.8 million | -6.1% | -2.7% |
| Dec 2025 | NT$272.1 million | -2.6% | -0.6% |
| Nov 2025 | NT$273.6 million | +0.7% | +0.6% |
| Oct 2025 | NT$271.9 million | +3.2% | +7.4% |
| Sep 2025 | NT$253.2 million | -6.4% | -6.2% |
| Aug 2025 | NT$269.9 million | -1.6% | +1.3% |
| Jul 2025 | NT$266.5 million | -0.5% | -1.0% |
| Jun 2025 | NT$269.1 million | +0.6% | -5.0% |
| May 2025 | NT$283.4 million | +4.9% | +7.2% |
| Apr 2025 | NT$264.4 million | -7.6% | -0.3% |
| Mar 2025 | NT$265.3 million | -2.4% | +5.9% |
| Feb 2025 | NT$250.5 million | -6.2% | -11.2% |
| Jan 2025 | NT$282.1 million | +1.0% | +1.0% |
| Dec 2024 | NT$279.3 million | +2.1% | +2.8% |
| Nov 2024 | NT$271.8 million | +2.4% | +3.1% |
| Oct 2024 | NT$263.5 million | -3.6% | -2.6% |
Jan–Oct 2026 cumulative: NT$2.7 billion (+0.7% YoY)
Other Biotech & Medical companies
Compare with peers: We Can Medicines vs PEC / We Can Medicines vs Lotus Pharm / We Can Medicines vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16